Literature DB >> 22301144

A replication-incompetent PB2-knockout influenza A virus vaccine vector.

Sylvia T Victor1, Shinji Watanabe, Hiroaki Katsura, Makoto Ozawa, Yoshihiro Kawaoka.   

Abstract

Vaccination is the primary form of protection from influenza virus infection. We recently developed a replication-incompetent PB2-knockout (PB2-KO) influenza virus that possesses a reporter gene (the green fluorescent protein gene) in the coding region of the PB2 segment. This virus replicated to high titers in PB2-expressing, but not unmodified, cells, suggesting its potential safety and feasibility as a vaccine. Here, we tested its efficacy in a murine model. The levels of IgG and IgA antibodies against influenza virus in sera, nasal washes, and bronchoalveolar lavage fluids of mice immunized with the PB2-KO virus were higher than those induced by a conventional inactivated vaccine. All PB2-KO virus-immunized mice survived challenges with lethal doses of influenza virus. Moreover, importantly, mice immunized with the PB2-KO virus produced antibodies against the reporter protein, suggesting that the PB2-KO virus has potential as a multivalent vaccine to combat infection with not only influenza virus but also other pathogens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301144      PMCID: PMC3318628          DOI: 10.1128/JVI.06232-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions.

Authors:  Yukiko Muramoto; Ayato Takada; Ken Fujii; Takeshi Noda; Kiyoko Iwatsuki-Horimoto; Shinji Watanabe; Taisuke Horimoto; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 2.  Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat.

Authors:  Alan W Hampson
Journal:  Ann Acad Med Singap       Date:  2008-06       Impact factor: 2.473

3.  Replication-incompetent influenza A viruses that stably express a foreign gene.

Authors:  Makoto Ozawa; Sylvia T Victor; Andrew S Taft; Shinya Yamada; Chengjun Li; Masato Hatta; Subash C Das; Emi Takashita; Satoshi Kakugawa; Eileen A Maher; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Gen Virol       Date:  2011-08-31       Impact factor: 3.891

4.  Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses.

Authors:  C T Hardy; S A Young; R G Webster; C W Naeve; R J Owens
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

5.  Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan.

Authors:  Kiyoko Iwatsuki-Horimoto; Taisuke Horimoto; Daisuke Tamura; Maki Kiso; Eiryo Kawakami; Shuji Hatakeyama; Yasuhiro Ebihara; Tomohiko Koibuchi; Takeshi Fujii; Kazuo Takahashi; Masayuki Shimojima; Yuko Sakai-Tagawa; Mutsumi Ito; Saori Sakabe; Ayaka Iwasa; Kei Takahashi; Takashi Ishii; Takeo Gorai; Koichiro Tsuji; Aikichi Iwamoto; Yoshihiro Kawaoka
Journal:  Clin Vaccine Immunol       Date:  2011-02-23

6.  Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.

Authors:  Shuji Hatakeyama; Yuko Sakai-Tagawa; Maki Kiso; Hideo Goto; Chiharu Kawakami; Keiko Mitamura; Norio Sugaya; Yasuo Suzuki; Yoshihiro Kawaoka
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

7.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.

Authors:  Anthony E Fiore; Timothy M Uyeki; Karen Broder; Lyn Finelli; Gary L Euler; James A Singleton; John K Iskander; Pascale M Wortley; David K Shay; Joseph S Bresee; Nancy J Cox
Journal:  MMWR Recomm Rep       Date:  2010-08-06

8.  Generation of influenza A viruses entirely from cloned cDNAs.

Authors:  G Neumann; T Watanabe; H Ito; S Watanabe; H Goto; P Gao; M Hughes; D R Perez; R Donis; E Hoffmann; G Hobom; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 9.  Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.

Authors:  Ronald B Moss; Richard T Davey; Roy T Steigbigel; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2010-04-07       Impact factor: 5.790

10.  Gene constellation of influenza A virus reassortants with high growth phenotype prepared as seed candidates for vaccine production.

Authors:  Andrew A Fulvini; Manojkumar Ramanunninair; Jianhua Le; Barbara A Pokorny; Jennifer Minieri Arroyo; Jeanmarie Silverman; Rene Devis; Doris Bucher
Journal:  PLoS One       Date:  2011-06-13       Impact factor: 3.240

View more
  16 in total

1.  A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.

Authors:  Ryuta Uraki; Maki Kiso; Kiyoko Iwatsuki-Horimoto; Satoshi Fukuyama; Emi Takashita; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

2.  Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 Vaccine.

Authors:  Aitor Nogales; Laura Rodriguez; Caroline Chauché; Kai Huang; Emma C Reilly; David J Topham; Pablo R Murcia; Colin R Parrish; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

3.  A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia.

Authors:  Ryuta Uraki; Zhenyu Piao; Yukihiro Akeda; Kiyoko Iwatsuki-Horimoto; Maki Kiso; Makoto Ozawa; Kazunori Oishi; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2015-06-29       Impact factor: 5.226

4.  Influenza A Virus Agnostic Receptor Tropism Revealed Using a Novel Biological System with Terminal Sialic Acid Knockout Cells.

Authors:  Haruhiko Kamiki; Shin Murakami; Takashi Nishikaze; Takahiro Hiono; Manabu Igarashi; Yuki Furuse; Hiromichi Matsugo; Hiroho Ishida; Misa Katayama; Wataru Sekine; Yasushi Muraki; Masateru Takahashi; Akiko Takenaka-Uema; Taisuke Horimoto
Journal:  J Virol       Date:  2022-07-18       Impact factor: 6.549

5.  A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus.

Authors:  Wendy Fonseca; Makoto Ozawa; Masato Hatta; Esther Orozco; Máximo B Martínez; Yoshihiro Kawaoka
Journal:  Arch Virol       Date:  2013-12-01       Impact factor: 2.574

Review 6.  Development and applications of single-cycle infectious influenza A virus (sciIAV).

Authors:  Aitor Nogales; Steven F Baker; William Domm; Luis Martínez-Sobrido
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

7.  Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Yu-Jin Kim; F Eun-Hyung Lee; Sang-Moo Kang
Journal:  Nanomedicine       Date:  2015-12-02       Impact factor: 5.307

8.  Generation and Characterization of Single-Cycle Infectious Canine Influenza A Virus (sciCIV) and Its Use as Vaccine Platform.

Authors:  Aitor Nogales; Kevin Chiem; Michael Breen; Marta L DeDiego; Colin R Parrish; Luis Martínez-Sobrido
Journal:  Methods Mol Biol       Date:  2022

Review 9.  Reverse Genetics Approaches for the Development of Influenza Vaccines.

Authors:  Aitor Nogales; Luis Martínez-Sobrido
Journal:  Int J Mol Sci       Date:  2016-12-22       Impact factor: 5.923

Review 10.  Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.

Authors:  Dan Zheng; Yinglei Yi; Ze Chen
Journal:  Viruses       Date:  2012-12-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.